Welcome to the insightful analysis on Orchid Pharma’s share price target for the years 2023, 2024, 2025, and beyond, with a focus on the possibility of the company reaching 1000 INR mark. Orchid Pharma, a prominent player in the pharmaceutical industry, has garnered significant attention from investors due to its consistent growth and strong product portfolio. By examining the company’s financial performance, market trends, and upcoming developments, this study aims to forecast potential share prices in the coming years and evaluate the feasibility of Orchid Pharma achieving the coveted 1000 INR milestone. Join us on this journey to gain valuable insights into the future prospects of Orchid Pharma’s share price and the factors that could influence its trajectory.
ORCHID PHARMA IN RECENT NEWS
- Orchid Pharma Ltd., a subsidiary of the Dhanuka Group, has managed to secure Rs 400 crore via a Qualified Institutional Placement (QIP). Notably, renowned investors such as the Massachusetts Institute of Technology and Societe Generale were granted shares in the company as part of this fundraising endeavor.
- Following the successful QIP fundraise of ₹400 crore, the promoter’s shareholding has undergone a significant shift. As of the June quarter, their ownership now stands at 72.40%, a notable reduction from the previous figure of 89.96% reported at the end of March 2023.
- Orchid Pharma made an announcement regarding its wholly-owned subsidiary, Orchid Bio Pharma, receiving approval to produce ‘7-ACA’ at an annual capacity of 1,000 tons.
HOW TO BUY ORCHID PHARMA SHARES IN INDIA?
- ICICI Direct
- HDFC Securities
- Angel Broking
ORCHID PHARMA SHARE PRICE TARGET 2023 TO 2025
Let’s examine the statistics regarding the projected share price target for the period between 2023 and 2025, after conducting a thorough review of the company.
ORCHID PHARMA SHARE PRICE TARGET FOR 2023
|When||Maximum Price||Minimum Price|
In 2023, Orchid Pharma’s share price has exhibited a gradual upward trend, indicating positive growth throughout the year. Starting from a Minimum Price of ₹505.23 in July, the share price steadily climbed, reaching ₹591.50 by December. The Maximum Price also showed a consistent rise, starting at ₹555.75 in July and ending at ₹574.27 in November. These price movements suggest that Orchid Pharma’s shares have experienced a favorable trajectory in 2023, and investors and analysts may set a target price for the stock based on this upward trend and the company’s performance.
ORCHID PHARMA SHARE PRICE TARGET FOR 2024
|When||Maximum Price||Minimum Price|
Established in 1992, Orchid Pharma is a vertically integrated company spanning the entire pharmaceutical value chain. In 2024, the company’s share price has shown a fluctuating pattern throughout the year. Starting the year at ₹622.63 in January, the share price peaked at ₹768.75 in December, showcasing substantial growth. However, the share price also experienced some dips, touching its lowest point at ₹450.34 in May. Considering the price movements and the company’s performance, investors and analysts may set varying share price targets for Orchid Pharma in 2024, taking into account both the growth potential and market conditions
ORCHID PHARMA SHARE PRICE TARGET FOR 2025
Share Price Target 2025
|Maximum Price||Minimum Price|
In 2025, Orchid Pharma’s share price appears to exhibit a mixed performance, experiencing fluctuations throughout the year. Starting the year at ₹784.13 in January, the share price reached its highest point at ₹932.51 in December. While there were periods of growth, such as in March and November, there were also months when the share price dipped, like in May and July. Investors and analysts evaluating Orchid Pharma’s potential share price target for 2025 should consider both the upward and downward movements, taking into account the company’s performance, market conditions, and industry developments to make informed projections.
ORCHID PHARMA SHARE PRICE TARGET FOR 2026 TO 2030
|Year||Maximum Price||Minimum Price|
Over the period from 2026 to 2030, Orchid Pharma’s share price has shown significant fluctuations and remarkable growth. Starting in 2026 with a Minimum Price of ₹750.67 and a Maximum Price of ₹1,072.39, the share price experienced a steady upward trajectory over the years. By 2029, the share price soared to a Maximum Price of ₹3,609.66, indicating a substantial increase in value. Although there were fluctuations in subsequent years, with the Maximum Price reaching ₹3,753.36 in 2030, the overall trend suggests a positive outlook for the company’s shares. Investors and analysts may find this historical data valuable in setting potential share price targets for Orchid Pharma in the coming years, considering the company’s performance, market dynamics, and industry trends.
ORCHID PHARMA FINANCIAL CONDITION (LAST 5 YEARS)
|Year||Mar 2019||Mar 2020||Mar 2021||Mar 2022||Mar 2023|
|Other Income +||218||24||15||67||52|
|Profit before tax||69||-131||-117||2||48|
|Net Profit +||69||-131||-117||-2||46|
|EPS in Rs||7.8||-32.11||-28.55||-0.48||11.35|
Over the five-year period from March 2019 to March 2023, Orchid Pharma’s financial condition appears to have experienced some fluctuations. The company’s sales figures declined from ₹600 million in March 2019 to ₹450 million in March 2021, but then showed improvement, reaching ₹666 million in March 2023. Similarly, the operating profit fluctuated, with negative values in 2019 and 2020 (-₹12 million and -₹31 million, respectively), but later turning positive, reaching ₹84 million in March 2023. The operating profit margin (OPM) also improved from -2% in March 2019 to 13% in March 2023, indicating better cost management and increased efficiency. Despite facing losses in March 2020 and March 2021, the company managed to turn profitable again in March 2023, recording a net profit of ₹46 million. These figures demonstrate Orchid Pharma’s ability to navigate challenges and strive for growth, potentially positioning the company on a more stable financial trajectory. However, investors and analysts should closely monitor future financial performance to assess the sustainability of this positive trend.
The share price target for Orchid Pharma by the end of 2023 is not explicitly stated. However, we can observe that the share prices have shown steady growth from July to December 2023, starting at ₹555.75 and reaching ₹591.50. Investors and analysts could potentially project further growth for the company’s shares in 2023 based on this positive trend.
The share price target for Orchid Pharma by the end of 2024 can be estimated. The share prices have been on an upward trajectory in 2024, starting at ₹622.63 in January and reaching ₹768.75 in December. This suggests the potential for continued growth in 2024, and investors and analysts may set share price targets based on the company’s performance and market conditions.
The share price target for Orchid Pharma by the end of 2025 can be anticipated. The share prices have continued to rise in 2025, with the Maximum Price reaching ₹932.51 in December. This indicates positive growth potential for the company’s shares in 2025, and investors and analysts may set share price targets considering the company’s performance and market dynamics.
Is it worthwhile to invest in Orchid Pharma for the long term?
Based on the data, Orchid Pharma has demonstrated long-term growth potential. The share prices have shown an upward trend over the years, indicating positive prospects for long-term investors. However, before making any investment decisions, it is essential to conduct thorough research, consider the company’s financial health, industry trends, and future growth prospects.
Will the Orchid Pharma stock continue to grow?
Orchid Pharma’s stock has shown consistent growth over the years. However, future growth is subject to various factors, including the company’s performance, industry dynamics, and overall market conditions. While past performance can provide valuable insights, investors should exercise caution and evaluate current and future factors before predicting future growth.
Will Orchid Pharma stock reach ₹1000 INR by 2025?
Based solely on the data provided, the share price of Orchid Pharma has not reached ₹1000 INR by 2025. However, the company has shown positive growth over the years, and the potential for reaching ₹1000 INR by 2025 cannot be definitively determined without considering additional factors. Investors should carefully analyze the company’s performance, market trends, and growth projections to assess the likelihood of reaching this target price.
Orchid Pharma from 2023 to 2030, we observe a consistent upward trend with intermittent fluctuations. The share prices have steadily increased over the years, indicating positive growth and potential for further expansion. While Orchid Pharma’s shares have not yet reached the ₹1,000 mark as of the provided data, the trajectory suggests that it is indeed possible for the company to reach this milestone in the future. The significant price increases from 2026 to 2030 indicate that Orchid Pharma is capable of sustained growth, and with continued positive performance and market conditions, reaching the ₹1,000 target may be within reach for the company in the coming years. However, it’s essential to keep in mind that market dynamics and various other factors can influence share prices, so investors and analysts should conduct thorough assessments before setting definitive targets.